| Literature DB >> 20171750 |
Wouter Crijns1, Tom Budiharto, Gilles Defraene, Jan Verstraete, Tom Depuydt, Karin Haustermans, Frank Van den Heuvel.
Abstract
This paper reports on an evaluation of 5 RapidArc optimization approaches vs IMRT. This study includes 11 patients with adenocarcinoma of the prostate. Rectal Normal Tissue Complication Probability is used as a constraint in a dose escalation. RapidArc rectal NTCP's are lower than those of IMRT (p = 0.007). This allows a mean dose escalation of 2.1 Gy([0.7 Gy,3.5 Gy]). Copyright 2010 Elsevier Ireland Ltd. All rights reserved.Entities:
Mesh:
Year: 2010 PMID: 20171750 DOI: 10.1016/j.radonc.2010.01.012
Source DB: PubMed Journal: Radiother Oncol ISSN: 0167-8140 Impact factor: 6.280